Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 6.63%, which has investors questioning if this is right time to ...

Kite Pharma has struck deals with China’s Fosun Pharma and Japan’s Daiichi Sankyo to develop and market its T-cell cancer immunotherapy technology in Asia. California-based Kite is one of ...

Gilead Sciences' Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Squibb over patents relating to CAR-T therapies, overturning a $1.2 billion fine levied ...

U.S. IND clearance follows recent approval of CTA for EPI-321 in facioscapulohumeral muscular dystrophy (FSHD) in New Zealand ...

They join Helen Kim and Rajul Jain on the firm’s leadership team. Kim and Jain have both been with Vida since 2019 and previously worked with Belldegrun at Kite Pharma.

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai ...

Mr. Camiolo has also held sales and marketing roles of increasing responsibility at Gilead Sciences, Inc., and was appointed Executive Director, Market Access Strategy, Pricing, and National Accounts ...